XML 65 R49.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Collaborative Research, Development and License Agreements - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Nov. 30, 2016 | Nov. 30, 2014 | Dec. 31, 2008 | Dec. 31, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2012 | Dec. 31, 2011
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |
Unused development funding advanced by AstraZeneca |  |  |  |  |  | $ 7,345,000 |  |  |
Accrued current liabilities |  |  |  | $ 11,192,000 | $ 11,192,000 | 15,337,000 |  |  |
Maximum |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |
Additional revenue recognized |  |  |  |  | 100,000,000 |  |  |  |
Astra Zeneca |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |
Collaboration Revenue |  |  |  |  |  |  | $ 5,400,000 |  | $ 3,000,000
Payments received for development work |  |  |  |  |  |  | 8,000,000 | $ 6,000,000 | $ 3,000,000
Additional collaboration revenue |  |  |  |  | 800,000 |  |  |  |
Milestone payments earned | $ 7,200,000 |  |  |  | 7,200,000 |  |  |  |
Unused development funding advanced by AstraZeneca |  |  |  |  |  | 7,400,000 |  |  |
Milestone revenue recognition |  |  |  | 7,200,000 | 103,000 | 1,635,000 | $ 2,174,000 |  |
Accrued current liabilities |  |  |  | 200,000 | 200,000 |  |  |  |
Deferred revenue |  |  |  | 0 | 0 | 2,700,000 |  |  |
Glaxo Smith Kline |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |
Collaboration Revenue |  | $ 2,500,000 | $ 10,000,000 |  |  |  |  |  |
Deferred revenue |  |  |  | $ 0 | $ 0 | $ 0 |  |  |

X
- Definition Accrued return of unused development funding to affiliate current. + References No definition available. + Details
Name: | dvax_AccruedReturnOfUnusedDevelopmentFundingToAffiliateCurrent
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Additional proceeds from collaborators. + References No definition available. + Details
Name: | dvax_AdditionalProceedsFromCollaborators
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Proceeds from development work. + References No definition available. + Details
Name: | dvax_ProceedsFromDevelopmentWork
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Proceeds from milestone payment. + References No definition available. + Details
Name: | dvax_ProceedsFromMilestonePayment
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |